This program project is focused on characterizing the interaction between host and donor cells that affect post transplant events including rejection, graft versus host disease, graft versus leukemia, and immune reconstitution. These interactions are mediated via effector T-cells or NK cells bearing the receptors for MHC molecules and bound peptides. Therefore, the MHC molecules are pivotal characterizing the functions of their receptors on the effector cells. All the research projects proposed in this program utilize various cellular reagents than demand a clear definition of MHC repertoire. Molecular typing or clining of the HLA alleles (for transfection) requires technical expertise as well as specialized facilities. The establishment of this core is justified by a need to centralize HLA typing service, provide HLA DNA clones for transfection, and take quality measurement of all cellular reagents which will be used for the research projects. Specifically, this core will provide: 1) A comprehensive typing of HLA class I and class II alleles. The molecular HLA typing will be used for typing the cellular reagents, and also for quality assurance measurement of already HLA typing cell lines, transfectants, DNA clones, and also for the BMT patient's specimen for their chimeric status; 2) The plasmids that contains a full length cDNA of desired HLA alleles cloned in a mammalian expression vector. We will customize the HLA alleles for cloning as requested by each project. The core will maintain a stock of each cDNA clone and provide the quality controlled plasmid with enough qunatity for the establishment of transfectant. The quality of the cDNAs will be assessed by resstriction mapping, oligotyping, or sequencing for every batch of plasmid preparation; and 3) A technical assistance for making transfectants expressing HLA class I alleles. The core will provide the investigators the commonly used transfection host cells (K562, 721, CIR, T2, and P815), and also provide basic protocols for transfection. If and when requested, this core will assist in solving technical problems or in setting the optimal parameters for transfection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA023766-23S1
Application #
6491044
Study Section
Project Start
2000-08-01
Project End
2002-02-28
Budget Start
Budget End
Support Year
23
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881

Showing the most recent 10 out of 452 publications